Not provided
Not provided
Not provided
Not provided
The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
Qualified patients will receive 10 mg of bardoxolone methyl once daily until the drug is available through commercial channels or until patient withdrawal, whichever is sooner. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bardoxolone methyl 10 mg | Experimental | Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bardoxolone methyl | Drug | Capsules of Bardoxolone methyl |
|
| Measure | Description | Time Frame |
|---|---|---|
| Long Term Safety as Measured by Incidence and Severity of Adverse Events During the Duration of the Study | Severity was defined using the following definitions: Mild: Symptoms causing no or minimal interference with usual social and functional activities; Moderate: Symptoms causing greater than minimal interference with usual social and functional activities; Severe: Symptoms causing inability to perform usual social and functional activities. | From time of first dose until the final visit, up to 172 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Banner University Medical Center, Phoenix Advanced Lung Disease Institute | Phoenix | Arizona | 85004 | United States | ||
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Bardoxolone Methyl | Participants who received bardoxolone methyl capsules (administered orally). Dosing started at 10 mg once daily (if enrolled under version 2.0, 2.1 [UK], 2.2 [Germany] of the protocol) or every other day (if enrolled under version 3.0, 3.1 [UK], 3.1 and 3.2 [Germany] of the protocol). For participants who began by dosing every other day, once daily dosing at 10 mg began at Week 4, unless contraindicated clinically. In Japan, participants began dosing at 5 mg once daily then dose-escalated to 10 mg at Week 4, unless contraindicated clinically. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol: US Protocol | Jul 16, 2018 | Sep 15, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Arizona Pulmonary Specialists |
| Phoenix |
| Arizona |
| 85012 |
| United States |
| Cedars Sinai Medical Center | Beverly Hills | California | 90211 | United States |
| University of California San Diego | La Jolla | California | 92093 | United States |
| VA Healthcare System of Greater Los Angeles | Los Angeles | California | 90073 | United States |
| David Geffen School of Medicine UCLA | Los Angeles | California | 90095 | United States |
| University of California Davis Medical Center - Division of Pulmonary and Critical Care | Sacramento | California | 95817 | United States |
| Harbor - UCLA Medical Center | Torrance | California | 90502 | United States |
| University of Colorado Denver - Division of Pulmonary Sciences | Aurora | Colorado | 80045 | United States |
| Georgetown University Medical Center - Department of Rheumatology | Washington D.C. | District of Columbia | 20007 | United States |
| University of Miami Miller School of Medicine | Miami | Florida | 33136 | United States |
| Cleveland Clinic of Florida | Weston | Florida | 33331 | United States |
| Augusta University | Augusta | Georgia | 30912 | United States |
| Piedmont-Georgia Lung | Austell | Georgia | 30106 | United States |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | United States |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | United States |
| University of Chicago | Chicago | Illinois | 60637 | United States |
| Kentuckiana Pulmonary Associates | Louisville | Kentucky | 40202 | United States |
| Maine Medical Center - Division of Pulmonary and Critical Care Medicine | Portland | Maine | 04102 | United States |
| Tufts Medical Center | Boston | Massachusetts | 02111 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | United States |
| Boston University School of Medicine | Boston | Massachusetts | 02118 | United States |
| University of Michigan | Ann Arbor | Michigan | 48109 | United States |
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| University of New Mexico Health Sciences Center | Albuquerque | New Mexico | 87131 | United States |
| Winthrop University Hospital | Mineola | New York | 11501 | United States |
| NYU Langone Medical Center | New York | New York | 10016 | United States |
| University of Rochester - University of Rochester Medical Center | Rochester | New York | 14642 | United States |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| The Lindner Clinical Trial Center | Cincinnati | Ohio | 45219 | United States |
| University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine | Cincinnati | Ohio | 45267 | United States |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | United States |
| Oklahoma Heart Hospital | Oklahoma City | Oklahoma | 73120 | United States |
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | United States |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | United States |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | United States |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | United States |
| The Methodist Hospital Research Institute | Houston | Texas | 77030 | United States |
| The University of Texas - Health Science Center & Medical School at Houston | Houston | Texas | 77030 | United States |
| University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics | Houston | Texas | 77030 | United States |
| University of Utah | Salt Lake City | Utah | 84132 | United States |
| Aurora Health Care | Milwaukee | Wisconsin | 53215 | United States |
| Centro Médico Dra de Salvo | Buenos Aires | Ciudad Autónoma de BuenosAires | C1426ABP | Argentina |
| Instituto de Investigaciones Clínicas Mar Del Plata | Buenos Aires | Mar Del Plata | B7600FZN | Argentina |
| Instituto de Cardiologia de Corrientes Juana Francisca Cabral | Corrientes | W3400AMZ | Argentina |
| Hospital Privado Centro Médico de Córdoba | Córdoba | X5016KEH | Argentina |
| Instituto Cardiovascular de Rosario | Rosario | S2000DSR | Argentina |
| Hospital Provincial Dr Jose Maria Cullen | Santa Fe | S3000EPV | Argentina |
| St Vincent's Hospital Sydney | Darlinghurst | New South Wales | 2010 | Australia |
| John Hunter Hospital | New Lambton | New South Wales | 2305 | Australia |
| Princess Alexandra Hospital | Brisbane | Queensland | 4102 | Australia |
| Royal Hobart Hospital | Hobart | Tasmania | 7000 | Australia |
| UZ Leuven | Leuven | Vlaams Brabant | 3000 | Belgium |
| Hospital Erasme | Brussels | 1070 | Belgium |
| Irmandade Da Santa Casa de Misericordia de Porto Alegre | Porto Alegre | Rio Grande do Sul | 90035-074 | Brazil |
| Hospital Dia do Pulmão | Blumenau | Santa Catarina | 89010-000 | Brazil |
| Instituto do Coração - HCFMUSP | São Paulo | 05403-900 | Brazil |
| Peter Lougheed Centre | Calgary | Alberta | T1Y 6J4 | Canada |
| Vancouver General Hospital | Vancouver | British Columbia | V5Z 1M9 | Canada |
| London Health Sciences Centre | London | Ontario | N6A 5W9 | Canada |
| Centre Hospitalier de l'Université Laval | Sainte-Foy | Quebec | G1V 4G5 | Canada |
| Vseobecna fakultni nemocnice v Praze | Prague | 128 00 | Czechia |
| Institut klinicke a experimentalni mediciny | Prague | 140 00 | Czechia |
| Universitatsklinkum Carl Gustav Carus an der Tu | Dresden | 01307 | Germany |
| Universitatsklinikum Hamburg Eppendorf | Hamburg | 20246 | Germany |
| Thorax Klinik | Heidelberg | 69126 | Germany |
| Hadassah University Hospital Ein Kerem | Jerusalem | 91120 | Israel |
| Rabin Medical Center | Petah Tikva | 49100 | Israel |
| Nippon Medical School Hospital | Tokyo | Bunkyo-ku | 113-8603 | Japan |
| Kobe University Hospital | Kobe | Hyōgo | 6500017 | Japan |
| Kitasato University Hospital | Sagamihara | Kanagawa | 252-0375 | Japan |
| Kyorin University Hospital | Tokyo | Mitaka-shi | 181-8611 | Japan |
| National Hospital Organization Okayama Medical Center | Okayama | Okayama-ken | 701-1192 | Japan |
| Chiba University Hospital | Chiba | 260-8677 | Japan |
| Hokkaido University Hospital | Sapporo | 0608648 | Japan |
| Kurume University Medical Center | Sendai | 980-8574 | Japan |
| National Cerebral and Cardiovascular Center | Suita | 5658565 | Japan |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Mexico City | Mexico City | 14000 | Mexico |
| Instituto Nacional de Cardiologia Dr. Ignacio Chavez | Mexico City | Mexico City | 14080 | Mexico |
| Hospital Universitario Dr. Jose Eleuterio Gonzalez | Nuevo León | Monterrey | 64460 | Mexico |
| Unidad de Investigación Clínica En Medicina SC | Monterrey | Nuevo León | 64718 | Mexico |
| Vrije Universiteit Amsterdam | Amsterdam | North Holland | 1007 MB | Netherlands |
| Philippine Heart Center | Quezon City | National Capital Region | 1100 | Philippines |
| Makati Medical Center | Makati | 1229 | Philippines |
| Philippine General Hospital (PGH) | Manila | Philippines |
| Hospital Universitario Marques de Valdecilla | Santander | Cantabria | Spain |
| Hospital Universitario Vall d'Hebron | Barcelona | 08035 | Spain |
| Hospital Universitario 12 de Octubre | Madrid | 28041 | Spain |
| Hospital Universitario Puerta de Hierro | Majadahonda | Spain |
| Hospital Virgen de La Salud | Toledo | 45004 | Spain |
| Golden Jubilee National Hospital | Glasgow | G81 4HX | United Kingdom |
| Royal Free Hospital | London | NW3 2QG | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety population (all patients who received at least 1 dose of bardoxolone methyl)
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Bardoxolone Methyl | Participants who received bardoxolone methyl capsules (administered orally). Dosing started at 10 mg once daily (if enrolled under version 2.0, 2.1 [UK], 2.2 [Germany] of the protocol) or every other day (if enrolled under version 3.0, 3.1 [UK], 3.1 and 3.2 [Germany] of the protocol). For participants who began by dosing every other day, once daily dosing at 10 mg began at Week 4, unless contraindicated clinically. In Japan, participants began dosing at 5 mg once daily then dose-escalated to 10 mg at Week 4, unless contraindicated clinically. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Long Term Safety as Measured by Incidence and Severity of Adverse Events During the Duration of the Study | Severity was defined using the following definitions: Mild: Symptoms causing no or minimal interference with usual social and functional activities; Moderate: Symptoms causing greater than minimal interference with usual social and functional activities; Severe: Symptoms causing inability to perform usual social and functional activities. | Safety population (all patients who received at least 1 dose of bardoxolone methyl) | Posted | Count of Participants | Participants | From time of first dose until the final visit, up to 172 weeks |
|
|
|
The time from the date of a participant's first dose to his or her last participation or event date, a maximum of 172 weeks
All AEs and SAEs from the time of administration of the first dose until the final visit were to be reported. AEs and SAEs that occurred within 30 days after the last dose were considered treatment emergent. For SAEs, the investigator was to follow the patient until the SAE subsided or until the condition became chronic in nature, stabilized (in the case of persistent impairment), or the patient died.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bardoxolone Methyl | Participants who received bardoxolone methyl capsules (administered orally). Dosing started at 10 mg once daily (if enrolled under version 2.0, 2.1 [UK], 2.2 [Germany] of the protocol) or every other day (if enrolled under version 3.0, 3.1 [UK], 3.1 and 3.2 [Germany] of the protocol). For participants who began by dosing every other day, once daily dosing at 10 mg began at Week 4, unless contraindicated clinically. In Japan, participants began dosing at 5 mg once daily then dose-escalated to 10 mg at Week 4, unless contraindicated clinically. | 17 | 261 | 106 | 261 | 198 | 261 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Agranulocytosis | Blood and lymphatic system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Anaemia | Blood and lymphatic system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Angina unstable | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Arteriosclerosis coronary artery | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Atrial flutter | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cardiac failure acute | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cardiac failure congestive | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cardio-respiratory arrest | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cardiogenic shock | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Coronary artery occlusion | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dilatation ventricular | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Left ventricular failure | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pericardial effusion | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pericarditis | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Right ventricular dysfunction | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Right ventricular failure | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Systolic dysfunction | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Vertigo | Ear and labyrinth disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Ascites | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Colitis ischaemic | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dental cyst | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Duodenitis | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Faecaloma | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Gastritis | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Haemorrhoids thrombosed | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Mallory-Weiss syndrome | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Oesophageal motility disorder | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Oesophageal stenosis | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Chest pain | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Complication associated with device | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Device related thrombosis | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Multiple organ dysfunction syndrome | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Non-cardiac chest pain | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Appendicitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Atypical pneumonia | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Bacteraemia | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Bursitis infective | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Cellulitis staphylococcal | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Clostridium difficile infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Diarrhoea infectious | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Ecthyma | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Haemophilus infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Herpes zoster | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Infectious colitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Lower respiratory tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Meningitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Pneumonia staphylococcal | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Respiratory tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Respiratory tract infection viral | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Septic shock | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Accidental overdose | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Cervical vertebral fracture | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Drug administration error | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Environmental exposure | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Eschar | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Joint injury | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Laceration | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Spinal compression fracture | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Thoracic vertebral fracture | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Norovirus test positive | Investigations | MedDRA (19.0) | Systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA (19.0) | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Fluid overload | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Malnutrition | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Costochondritis | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Scleroderma | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Spinal deformity | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Systemic lupus erythematosus | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Intraductal proliferative breast lesion | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (19.0) | Systematic Assessment |
| |
| Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (19.0) | Systematic Assessment |
| |
| Salivary gland cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (19.0) | Systematic Assessment |
| |
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (19.0) | Systematic Assessment |
| |
| Squamous cell carcinoma of lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (19.0) | Systematic Assessment |
| |
| Cerebellar artery thrombosis | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Embolic stroke | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Hepatic encephalopathy | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Lateral medullary syndrome | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Lumbar radiculopathy | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Metabolic encephalopathy | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Presyncope | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Spinal epidural haematoma | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Subarachnoid haemorrhage | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Vasculitis cerebral | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Acute kidney injury | Renal and urinary disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Urinary retention | Renal and urinary disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Menometrorrhagia | Reproductive system and breast disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Ovarian cyst ruptured | Reproductive system and breast disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Acute respiratory distress syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Interstitial lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pulmonary arterial hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Haematoma | Vascular disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Shock | Vascular disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Thrombophlebitis | Vascular disorders | MedDRA (19.0) | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Non-cardiac chest pain | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Conjunctivitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Herpes zoster | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Lower respiratory tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Respiratory tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (19.0) | Systematic Assessment |
| |
| Arthropod bite | Injury, poisoning and procedural complications | MedDRA (19.0) | Systematic Assessment |
| |
| Brain natriuretic peptide increased | Investigations | MedDRA (19.0) | Systematic Assessment |
| |
| N-terminal prohormone brain natriuretic peptide increased | Investigations | MedDRA (19.0) | Systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA (19.0) | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Vitamin D deficiency | Metabolism and nutrition disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pain in jaw | Musculoskeletal and connective tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pulmonary arterial hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA (19.0) | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA (19.0) | Systematic Assessment |
|
Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| US Biogen Clinical Trial Center | Biogen | 866-633-4636 | clinicaltrials@biogen.com |
| Prot_000.pdf |
| Prot | Yes | No | No | Study Protocol: Japan Protocol | Jul 25, 2018 | Sep 15, 2023 | Prot_001.pdf |
| Prot | Yes | No | No | Study Protocol: UK Protocol | Jul 16, 2018 | Sep 15, 2023 | Prot_002.pdf |
| Prot | Yes | No | No | Study Protocol: Germany Protocol | Jul 11, 2019 | Sep 15, 2023 | Prot_003.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 5, 2020 | Sep 15, 2023 | SAP_004.pdf |
Not provided
| ID | Term |
|---|---|
| D006976 | Hypertension, Pulmonary |
| D000081029 | Pulmonary Arterial Hypertension |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C445068 | bardoxolone methyl |
Not provided
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Czechia |
|
| Japan |
|
| Philippines |
|
| United Kingdom |
|
| Spain |
|
| Canada |
|
| Netherlands |
|
| Belgium |
|
| Brazil |
|
| Mexico |
|
| Israel |
|
| Australia |
|
| Germany |
|
|
| Number and percent of participants with worst adverse event severity of mild |
|
| Number and percent of participants with worst adverse event severity of moderate |
|
| Number and percent of participants with worst adverse event severity of severe |
|